Predictors of 30-day readmissions post-CAR-T in patients with relapsed/refractory multiple myeloma using the United States nationwide readmission database

Abstract B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy has changed the therapeutic landscape of relapsed/refractory multiple myeloma (RRMM). Despite the efficacy, these products have been associated with an adverse effect profile including cytokine releas...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Raj Shah, Nikhil Vojjala, Tiewei Cheng, Charmi Bhanushali, Sanjana Mullangi, Leyla Shune, Reza Shahzad
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Springer 2026-03-01
Ráidu:	Annals of Hematology
Fáttát:	Multiple Myeloma CAR-T Relapsed Refractory
Liŋkkat:	https://doi.org/10.1007/s00277-026-06927-z
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!